Destiny Pharma #DEST – Developing Novel Medicines that Prevent Serious Infections. Alan Green talks to CEO Neil Clark October 15, 2021 – Posted in: Blog – Tags: brand communications ceo alan green, China Medical Systems, dest, destiny pharma, Neil Clark, novus communications CEO alan green, NTCD-M3, Spore COV, XF-73
- Two exciting late stage clinical assets – XF-73 and NTCD-M3
- China Medical Systems – new XF-73 programme in China
- NTCD-M3 Phase 3 studies
- Spore COV – JV progress and Innovate funding
- Cash runway and upcoming value inflection points